LAURUSLABS - Laurus Labs
📢 Recent Corporate Announcements
Laurus Labs Limited has made the audio recording of its Q4 FY26 earnings conference call available to the public. The call was hosted on April 30, 2026, following the announcement of the company's quarterly financial results. This disclosure is a routine regulatory requirement under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The recording provides management's detailed commentary on the company's performance and future strategy.
- Q4 FY26 results conference call hosted on April 30, 2026
- Audio recording link provided in compliance with SEBI Regulation 30 & 46
- Follows the initial results intimation previously dated April 09, 2026
- Provides transparency for shareholders unable to attend the live call
Laurus Labs has announced the appointment of Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors for five-year terms starting July 02, 2026. Dr. Mande is a distinguished scientist and former Director General of CSIR, while Ms. Banerjee brings over 30 years of experience in global financial services and wealth management. These appointments coincide with the retirement of Mrs. Aruna Bhinge, who will complete her second term on July 06, 2026. The addition of high-caliber experts from scientific and financial domains is expected to strengthen the board's strategic oversight.
- Dr. Shekhar Chintamani Mande appointed as Independent Director for a 5-year term effective July 02, 2026.
- Ms. Sutapa Banerjee appointed as Independent Director for a 5-year term effective July 02, 2026.
- Mrs. Aruna Bhinge to retire on July 06, 2026, after completing two full terms as an Independent Director.
- New directors bring expertise from the Council of Scientific and Industrial Research (CSIR) and major banks like ANZ Grindlays and ABN AMRO.
Laurus Labs has approved the voluntary closure of its step-down wholly owned subsidiary, Laurus Generics GmbH, based in Germany. The subsidiary was non-material and reported zero turnover for the financial year ending March 31, 2026. It held a negative net worth of approximately 1.05 million Euros at the time of the decision. Management has confirmed that this closure will not have any material impact on the company's consolidated financial performance.
- Voluntary closure of step-down subsidiary Laurus Generics GmbH (Germany) approved by the Board.
- The subsidiary reported Nil turnover for the financial year ended March 31, 2026.
- Net worth of the German unit was negative 1,053,091 Euros as of March 31, 2026.
- The closure is subject to regulatory approvals in Germany and will not impact core operations.
Laurus Labs has approved an additional investment of up to EUR 9.8 million in its joint venture, KRKA Pharma Private Limited. The Slovenian co-venturer, KRKA d.d., will also invest approximately EUR 10.2 million, maintaining the existing 49:51 shareholding ratio. These funds are specifically designated for capital expenditure to establish a new manufacturing facility in India. The JV, incorporated in 2024, is currently providing R&D services and reported a turnover of INR 10.47 million in FY26.
- Laurus Labs to invest up to EUR 9.8 million (approx. INR 88-90 Cr) in KRKA Pharma JV
- Co-venturer KRKA d.d. Slovenia to invest EUR 10.2 million to maintain 51% stake
- Investment proceeds will be used for setting up a new manufacturing facility
- Laurus Labs will maintain its 49% equity stake in the joint venture
- The investment is scheduled to be completed during the financial year 2026-27
Laurus Labs has announced the appointment of two high-profile Independent Directors, Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee, for five-year terms starting July 2, 2026. Dr. Mande is a renowned scientist and former Director General of CSIR, while Ms. Banerjee is a veteran in financial services and wealth management. These appointments follow the scheduled retirement of Mrs. Aruna Bhinge on July 6, 2026, after a 10-year tenure. The inclusion of such experts is expected to bolster the company's strategic oversight in R&D and financial governance.
- Dr. Shekhar Chintamani Mande appointed as Independent Director for a 5-year term starting July 2, 2026.
- Ms. Sutapa Banerjee appointed as Independent Director for a 5-year term starting July 2, 2026.
- Mrs. Aruna Bhinge to retire on July 6, 2026, after completing two consecutive 5-year terms.
- New directors bring significant expertise from CSIR (scientific research) and top-tier banking/wealth management.
Laurus Labs has approved a second interim dividend of Rs 1.20 per equity share for the financial year 2025-26, which represents 60% of the face value of Rs 2. The company has designated May 08, 2026, as the record date to identify eligible shareholders for this distribution. The dividend is scheduled to be paid to shareholders on or after May 20, 2026. This move reflects the company's continued commitment to returning value to its shareholders during the fiscal year.
- Approved 2nd interim dividend of Rs 1.20 per equity share for FY 2025-26
- Dividend payout represents 60% of the face value of Rs 2 per share
- Record date for determining shareholder eligibility is fixed as May 08, 2026
- Dividend payment will be processed on or after May 20, 2026
Laurus Labs reported a robust performance for FY26, with total revenues growing 23% to ₹6,813 crore, driven by a 36% surge in the CDMO segment. Net profit witnessed a massive 148% increase to ₹889 crore, supported by a significant expansion in EBITDA margins to 26.8% from 20.1% in the previous year. The company is successfully de-risking its portfolio by reducing dependence on ARV APIs and increasing its high-margin CDMO and generic FDF contributions. With a ₹1,070 crore capex in FY26 and a long-term $600 million investment plan for a new Vizag site, the company is positioning itself for sustained high-tech pharmaceutical growth.
- FY26 Revenue grew 23% YoY to ₹6,813 Cr, with CDMO segment contributing 31% of total revenue mix.
- Net Profit jumped 148% to ₹889 Cr, while EBITDA margins expanded by 670 bps to 26.8%.
- Net Debt-to-EBITDA significantly improved to 1.3x from 2.3x in the previous year due to better cash flows.
- Company executed ₹1,070 Cr in Capex during FY26, focusing on ADC, Gene Therapy, and Peptides.
- ROCE nearly doubled to 17.7% in FY26 compared to 9.7% in FY25, reflecting improved operating leverage.
Laurus Labs has approved an investment of up to €9.8 million in its joint venture, KRKA Pharma Private Limited, to fund the construction of a new manufacturing facility. The co-venturer, KRKA d.d., will also invest €10.2 million, ensuring the 51:49 shareholding ratio remains unchanged. Simultaneously, the company is strengthening its board by appointing Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors. The board also approved the closure of its non-operational German subsidiary, which had zero revenue in FY26, to streamline operations.
- Investment of up to €9.8 million in KRKA Pharma JV to fund a new manufacturing plant.
- JV partner KRKA d.d. to invest €10.2 million, maintaining Laurus Labs' 49% stake.
- Appointment of Dr. Shekhar Mande (ex-DG, CSIR) and Ms. Sutapa Banerjee as Independent Directors for 5-year terms.
- Voluntary closure of Laurus Generics GmbH (Germany) which reported zero turnover in FY26.
- KRKA Pharma JV reported a turnover of INR 10.47 million in FY26 during its R&D phase.
Laurus Labs reported a robust financial performance for the fiscal year ended March 31, 2026, with annual consolidated revenue growing 23% to ₹6,812.90 crore. The company's net profit for FY26 saw a massive jump of 151%, reaching ₹889.85 crore compared to ₹354.41 crore in the previous year. For the fourth quarter alone, net profit stood at ₹281.91 crore, nearly a four-fold increase from the ₹73.45 crore reported in Q4 FY25. Additionally, the board has approved a second interim dividend of ₹1.20 per share, rewarding shareholders for the strong performance.
- Annual Consolidated Revenue increased by 22.7% YoY to ₹6,812.90 crore in FY26.
- Full-year Net Profit grew by 151% YoY to ₹889.85 crore from ₹354.41 crore in FY25.
- Q4 FY26 Net Profit rose to ₹281.91 crore, a significant jump from ₹73.45 crore in the year-ago quarter.
- Declared a 2nd interim dividend of ₹1.20 per share (60% of face value) with a record date of May 08, 2026.
- Earnings Per Share (EPS) for FY26 improved significantly to ₹16.47 from ₹6.65 in the previous fiscal.
Laurus Labs has responded to NSE's clarification request regarding technical discrepancies in its September 2025 financial filings, attributing them to portal glitches and inadvertent selection errors. Despite these procedural lapses, the company's financial performance for Q2 FY26 shows a significant recovery, with revenue growing to ₹1,653.47 crore from ₹1,223.70 crore YoY. Net profit surged to ₹194.49 crore compared to just ₹19.95 crore in the previous year's corresponding quarter. The company has also confirmed an interim dividend of ₹0.80 per share.
- Revenue from operations increased 35% YoY to ₹1,653.47 crore for the quarter ended September 30, 2025
- Net profit witnessed a massive jump to ₹194.49 crore in Q2 FY26 from ₹19.95 crore in Q2 FY25
- Board approved an interim dividend of ₹0.80 per equity share (40% of face value) for FY 2025-26
- Company rectified XBRL filing discrepancies and submitted revised machine-readable financial results
- H1 FY26 total income reached ₹3,260.43 crore, a significant rise from ₹2,425.72 crore in H1 FY25
Laurus Labs has filed the mandatory compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The certificate, provided by KFin Technologies Limited, confirms that securities received for dematerialization have been processed and the necessary details have been furnished to the stock exchanges. This is a standard administrative procedure to ensure the accuracy of shareholding records between the company and depositories like NSDL and CDSL. The filing indicates that the company is adhering to routine regulatory reporting timelines.
- Compliance certificate submitted for the quarter ended March 31, 2026.
- Confirmation provided by Registrar and Share Transfer Agent, KFin Technologies Limited.
- Covers processing of dematerialization and rematerialization requests as per SEBI norms.
- Filing submitted to both BSE and National Stock Exchange (NSE) on April 15, 2026.
Laurus Labs has scheduled its Q4 and Full Year FY26 earnings conference call for April 30, 2026, at 5:00 PM IST. The company previously reported an annual revenue of ₹5,554 crore for FY2025 and continues to focus on its API and CDMO segments. The call, hosted by DAM Capital Advisors, will provide management insights into the company's performance across its 15 manufacturing sites and R&D progress involving 1,250+ scientists.
- Earnings conference call for Q4 and FY26 results scheduled for April 30, 2026.
- Company reported a total annual revenue of ₹5,554 crore in the previous fiscal year (FY2025).
- Laurus Labs maintains a strong R&D focus with over 1,250 scientists and 15 global-agency-approved sites.
- The company holds global leadership positions in APIs for Anti-retroviral, Oncology, and Cardiovascular therapeutics.
Laurus Labs Limited has informed the stock exchanges that its trading window for dealing in company securities will be closed starting April 1, 2026. This closure is a mandatory compliance step under SEBI Insider Trading regulations prior to the announcement of audited financial results for the quarter and full year ending March 31, 2026. The window will remain closed for all designated persons and their relatives until 48 hours after the results are declared. The specific date for the board meeting to approve these results is yet to be announced.
- Trading window closure effective from April 1, 2026
- Pertains to audited financial results for the quarter and year ended March 31, 2026
- Restriction applies to all designated persons, immediate relatives, and connected persons
- Window to reopen 48 hours after the official financial results declaration
Laurus Labs has recommended the appointment of S.R. Batliboi & Associates LLP as its new Statutory Auditors for a five-year term starting from the 2027 AGM. This change is a routine regulatory requirement as the current auditors, Deloitte Haskins & Sells LLP, will complete their mandatory second term in 2027. The appointment will span from the conclusion of the 22nd AGM in 2027 until the 27th AGM in 2032. The transition is subject to shareholder approval at the upcoming 2027 Annual General Meeting.
- S.R. Batliboi & Associates LLP recommended for a 5-year term from 2027 to 2032
- Current auditors Deloitte Haskins & Sells LLP to exit after completing their second term in 2027
- Appointment is subject to shareholder approval at the 22nd Annual General Meeting
- New auditors have extensive experience in the pharmaceutical and industrial sectors
- The Board meeting for this recommendation concluded on March 12, 2026
Laurus Labs Limited has scheduled an in-person interaction with a group of analysts and institutional investors on March 18, 2026. The meeting will take place in Visakhapatnam and will include a facility visit alongside management discussions. This event is part of the company's regular investor engagement program under SEBI Regulation 30. The company has explicitly stated that no unpublished price sensitive information will be shared during this interaction.
- In-person meeting and facility visit scheduled for March 18, 2026, in Visakhapatnam
- Interaction involves a group of analysts and institutional investors
- Compliance filing pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015
- Company confirms no Unpublished Price Sensitive Information (UPSI) will be disclosed
Financial Performance
Revenue Growth by Segment
Consolidated Gross Income grew 10.17% to INR 5,554 Cr in FY25 from INR 5,041 Cr in FY24. The CDMO segment is expected to scale up significantly in FY26 to drive future growth, following a 16.5% decline in FY24 total operating income (INR 5,044 Cr vs INR 6,041 Cr in FY23) due to lower contract manufacturing contributions.
Geographic Revenue Split
Europe is a primary market contributing 36% of total revenue and 62% of export revenue. The US market contributes less than 10% of total revenue, which limits the company's exposure to USFDA regulatory volatility.
Profitability Margins
Gross margins have expanded from historical levels of 50% to approximately 60% in Q2 FY26 due to a shift toward commercial-stage CDMO programs and leadership in ARV/Oncology. Net Profit After Tax (PAT) surged 122% to INR 358 Cr in FY25 from INR 161 Cr in FY24.
EBITDA Margin
EBITDA margin stood at 20.1% in FY25 (INR 1,115 Cr), a significant improvement from 15.8% in FY24. In Q2 FY26, EBITDA margins expanded by 11 percentage points YoY to reach 26% driven by better asset utilization and product mix.
Capital Expenditure
Laurus Labs has planned a capital expenditure of approximately INR 1,500 Cr over the next two years (FY26-FY27) to support specialized modalities like gene therapy, ADC, and fermentation.
Credit Rating & Borrowing
The company holds a 'CARE AA; Stable' rating for long-term facilities (reaffirmed in July 2025) and 'CARE A1+' for short-term facilities. Interest coverage improved to 4.90x in FY25 from 4.28x in FY24.
Operational Drivers
Raw Materials
Key raw materials include chemical intermediates for Active Pharmaceutical Ingredients (APIs) in Anti-Retroviral (ARV), Oncology, Cardiovascular, and Gastro therapeutics. Specific inputs include bio-enzyme catalysts and fermentation-based ingredients.
Import Sources
Not explicitly disclosed in available documents, though the company utilizes natural hedging by netting off imports and exports to mitigate currency risk.
Capacity Expansion
The company operates 15 facilities (including 12 manufacturing sites: 8 in Vizag, 2 in Hyderabad, 2 in Bangalore). New capacity for Laurus Bio is expected to come online by the end of 2026 to support revenue ramp-up in FY27.
Raw Material Costs
Raw material costs are managed through a focus on backward integration and green chemistry platforms like continuous flow chemistry to improve yield and reduce waste.
Manufacturing Efficiency
Efficiency is driven by high asset utilization and a shift from clinical-phase drug development to commercial manufacturing in the CDMO segment.
Strategic Growth
Expected Growth Rate
20%
Growth Strategy
Growth will be achieved through the scale-up of the CDMO segment in FY26, a Joint Venture with KRKA Pharma for new markets, and investments in an ADC (Antibody Drug Conjugate) technology platform. The company is also expanding into specialized modalities like gene therapy and fermentation.
Products & Services
Active Pharmaceutical Ingredients (APIs) for ARV, Oncology, and Cardiovascular treatments; Finished Dosage Forms (FDF); CDMO services for global innovators; and Bio-ingredients.
Brand Portfolio
Laurus Labs, Laurus Bio, Laurus Synthesis, Laurus Generics.
New Products/Services
New ADC integrated services and gene therapy manufacturing are expected to contribute to revenue as capacities come online by end of 2026.
Market Expansion
Expansion is targeted through the KRKA JV and increasing the pipeline of commercial CDMO programs.
Market Share & Ranking
Laurus holds a global leadership position in select APIs, including anti-retrovirals and oncology drugs.
Strategic Alliances
Joint Venture with KRKA Pharma Private Limited; 26% stake in Kurnool Renewables for green energy; investment in an ADC technology platform company.
External Factors
Industry Trends
The CDMO industry is shifting toward early-stage involvement requiring large upfront CAPEX. Laurus is positioning itself by investing in specialized modalities like ADCs and cell/gene therapy to capture this 15-20% industry growth trend.
Competitive Landscape
Competes with other large CDMO and API players like Divi's Labs. Competition is based on manufacturing scale, regulatory track record, and technical capabilities in complex chemistry.
Competitive Moat
Moat is built on cost leadership in ARV APIs, deep backward integration, and a large R&D talent pool (2,600+ scientists). This is sustainable due to high entry barriers in complex API manufacturing.
Macro Economic Sensitivity
Sensitive to global healthcare spending and pharmaceutical outsourcing trends, particularly in the CDMO sector.
Consumer Behavior
Demand for ARV drugs remains stable; however, a shift toward preventive drugs (PrEP) is monitored, though not expected to have a material impact in the near term.
Geopolitical Risks
Exposure to diverse geographies requires compliance with evolving international regulations; non-compliance can lead to product recalls or reputational damage.
Regulatory & Governance
Industry Regulations
Operations are governed by USFDA, WHO Geneva, ANVISA Brazil, and EMA standards. 7 of 12 sites are USFDA approved. Compliance is critical as non-compliance can lead to import alerts.
Environmental Compliance
Invested in green chemistry and renewable energy (26% stake in Kurnool Renewables). ESG scores improved significantly (S&P score from 59 to 73).
Taxation Policy Impact
The consolidated tax rate is approximately 28%. The parent company has converted to a new tax regime, while subsidiaries operate under different rates.
Legal Contingencies
The company maintains internal financial controls and conducts regular audits to ensure compliance with the Companies Act 2013 and other statutory requirements. Specific pending litigation values are not disclosed.
Risk Analysis
Key Uncertainties
Execution risk of large-scale CAPEX (INR 1,500 Cr) and the timing of CDMO order inflows are key uncertainties that could impact profitability by 5-10% if delayed.
Geographic Concentration Risk
High concentration in Europe (36% of revenue) makes the company sensitive to European regulatory shifts and economic stability.
Third Party Dependencies
Dependency on innovator companies for CDMO contracts; delays in their clinical trials or commercial launches directly impact Laurus's revenue.
Technology Obsolescence Risk
Risk of new drug classes replacing current APIs. Mitigated by investing in new technologies like ADCs and gene therapy.
Credit & Counterparty Risk
Liquidity is 'Strong' with gross cash accruals of INR 750 Cr in FY25 against repayment obligations of ~INR 320 Cr, indicating high receivables quality.